Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

EyeFortin is intricately fabricated to support strong vision and to promote healthy functioning of the eyes. It contains ...

New research from the Guangdong Academy of Medical Sciences has found that certain eye conditions, like age-related macular ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Citi has initiated coverage of EyePoint (EYPT) with a buy rating, stating it sees the company's drug Duravyu as well-positioned to compete in the wAMD market. Read more here.

Rates of nearsightedness, or myopia, are skyrocketing in kids—and scientists say it has to do with how little time they’re ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

As Americans become increasingly skeptical of technology's role in our society, can a trade show like CES help usher back an ...